Cardiovascular Systems Inc. (NASDAQ:CSII) Director Edward M. Brown sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, November 15th. The shares were sold at an average price of $24.95, for a total transaction of $249,500.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Shares of Cardiovascular Systems Inc. (NASDAQ:CSII) opened at 26.88 on Friday. The company’s market capitalization is $888.73 million. Cardiovascular Systems Inc. has a 12 month low of $7.50 and a 12 month high of $27.38. The company’s 50-day moving average is $24.01 and its 200 day moving average is $20.76.

Cardiovascular Systems (NASDAQ:CSII) last released its quarterly earnings results on Wednesday, October 26th. The medical device company reported ($0.06) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.19) by $0.13. The business earned $49.80 million during the quarter, compared to analyst estimates of $205.50 million. Cardiovascular Systems had a negative net margin of 24.24% and a negative return on equity of 30.19%. The company’s quarterly revenue was up 13.5% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.41) earnings per share. On average, equities research analysts anticipate that Cardiovascular Systems Inc. will post ($0.21) earnings per share for the current year.

Insider Buying and Selling by Quarter for Cardiovascular Systems (NASDAQ:CSII)

A number of research firms have weighed in on CSII. Feltl & Co. upgraded shares of Cardiovascular Systems from a “buy” rating to a “strong-buy” rating and set a $30.00 price objective for the company in a research note on Thursday, October 27th. Bank of America Corp. upgraded shares of Cardiovascular Systems from an “underperform” rating to a “neutral” rating in a research note on Thursday, August 4th. Zacks Investment Research upgraded shares of Cardiovascular Systems from a “hold” rating to a “buy” rating and set a $25.00 price target for the company in a research note on Monday, October 31st. JMP Securities initiated coverage on shares of Cardiovascular Systems in a research note on Friday, October 7th. They issued an “outperform” rating and a $35.00 price target for the company. Finally, Leerink Swann upgraded shares of Cardiovascular Systems from a “market perform” rating to an “outperform” rating and set a $30.00 price target for the company in a research note on Monday, August 22nd. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $27.50.

Several hedge funds have recently added to or reduced their stakes in the stock. GSA Capital Partners LLP purchased a new stake in Cardiovascular Systems during the second quarter valued at approximately $393,000. State Board of Administration of Florida Retirement System raised its stake in Cardiovascular Systems by 17.7% in the second quarter. State Board of Administration of Florida Retirement System now owns 26,314 shares of the medical device company’s stock valued at $484,000 after buying an additional 3,957 shares during the last quarter. Gamco Investors INC. ET AL raised its stake in Cardiovascular Systems by 0.3% in the second quarter. Gamco Investors INC. ET AL now owns 36,400 shares of the medical device company’s stock valued at $669,000 after buying an additional 100 shares during the last quarter. California Public Employees Retirement System raised its stake in Cardiovascular Systems by 9.5% in the second quarter. California Public Employees Retirement System now owns 22,000 shares of the medical device company’s stock valued at $404,000 after buying an additional 1,900 shares during the last quarter. Finally, Swiss National Bank raised its stake in Cardiovascular Systems by 14.1% in the second quarter. Swiss National Bank now owns 50,900 shares of the medical device company’s stock valued at $935,000 after buying an additional 6,300 shares during the last quarter. 67.75% of the stock is owned by institutional investors and hedge funds.

Cardiovascular Systems Company Profile

Cardiovascular Systems, Inc is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company develops an orbital atherectomy technology for both peripheral and coronary commercial applications.

5 Day Chart for NASDAQ:CSII

Receive News & Stock Ratings for Cardiovascular Systems Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems Inc. and related stocks with our FREE daily email newsletter.